Glow-in-the-Dark cancer detector aims to cut repeat breast surgeries
NCT ID NCT07616856
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will test a device called LumiSystem that helps surgeons see if any cancer cells are left behind during breast cancer surgery. About 1500 women having a lumpectomy will be included. The goal is to see if using this imaging tool reduces the number of patients who need a second surgery because cancer was left behind.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LumiSystem (imaging device and fluorescent imaging agent)
- What this could lead to
- If successful, this could help surgeons remove more cancer during breast cancer surgery, reducing the need for repeat operations.
- What could go wrong
- This is an observational registry, not a controlled trial, so it cannot prove the device improves long-term outcomes. Results may vary across hospitals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?